Key clinical point: Eta (14-3-3η) protein could serve as a potential biomarker in the differential diagnosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) because patients with PsA showed significantly lower serum levels of eta protein than patients with RA.
Major finding: Eta protein levels were significantly lower in patients with PsA vs RA (regression coefficient [B], −0.341, odds ratio [OR], 0.711; P = .007). A cutoff value of 2.64 ng/mL for eta protein could distinguish between PsA and RA with 54.7% sensitivity and 77.8% specificity (area under the curve, 0.686; P = .001).
Study details: This case-control study included 54 patients with PsA, 53 with RA, and 56 healthy individuals without any rheumatological disease, whose eta protein levels were detected using enzyme-linked immunosorbent assay.
Disclosures: This study was funded by a grant from the Turkish Rheumatology Association. The authors declared no conflict of interests.
Source: Kor A, Orhan K, Maraş Y, et al. Does Eta protein differentiate rheumatoid arthritis from psoriatic arthritis? Curr Med Chem. Published online April 27, 2024 . Source